PURE Bioscience Announces Distribution Agreement with ChemStation
01 Agosto 2024 - 1:02PM
Business Wire
PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or
“we”), creator of the patented non-toxic silver dihydrogen citrate
(SDC) antimicrobial, and ChemStation Buyers Association, Inc.
(“ChemStation”), have entered into a multi-year distribution
agreement for the purchase and selling of SDC products under
special terms and conditions.
Tim Steffensmeier, Vice President of Sales, said, “PURE
Bioscience’s SDC product profiles align well with ChemStation’s
commitment to delivering safe and effective custom cleaning
solutions with regard for the environment. We are excited to
partner with them as they extend their products to the food
industry throughout North America.”
How SDC Works
SDC kills microorganisms by two modes of action: 1) the silver
ion deactivates structural and metabolic membrane proteins leading
to microbial death; 2) the microbes view SDC as a food source,
allowing the silver ion to enter the microbe. Once inside the
organism, the silver ion denatures the DNA, which halts the
microbe’s ability to replicate and leads to its death. This dual
action makes SDC highly and quickly effective against a broad
spectrum of microbes. Traditional silver-based disinfectants have
short shelf lives – from hours to days. SDC is a stabilized silver
ion complex with a shelf life of several years. The unique bond
between the silver ion in SDC allows the silver ion to remain in
solution while at the same time making it more bio-available for
antimicrobial action.
About PURE Bioscience, Inc.
PURE is focused on developing and commercializing our
proprietary antimicrobial products primarily in the food safety
arena. We provide solutions to combat the health and environmental
challenges of pathogen and hygienic control. Our technology
platform is based on patented, stabilized ionic silver, and our
initial products contain silver dihydrogen citrate, better known as
SDC. This is a broad-spectrum, non-toxic antimicrobial agent, and
formulates well with other compounds. As a platform technology, SDC
is distinguished from existing products in the marketplace because
of its superior efficacy, reduced toxicity, and mitigation of
bacterial resistance. PURE’s mailing address of 771 Jamacha Rd.
#512, El Cajon, California 92019 (San Diego County area) serves as
its official address for all business requirements. Additional
information on PURE is available at www.purebio.com.
Forward-looking Statements: Any statements contained in
this press release that do not describe historical facts may
constitute forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. Statements in
this press release, including quotes from management, concerning
the Company’s expectations, plans, business outlook, future
performance, future potential revenues, expected results of the
Company’s marketing efforts, the execution of contracts under
negotiation and any other statements concerning assumptions made or
expectations as to any future events, conditions, performance or
other matters, are “forward-looking statements.” Forward-looking
statements inherently involve risks and uncertainties that could
cause our actual results to differ materially from any
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, the Company’s
failure to implement or otherwise achieve the benefits of its
proposed business initiatives and plans; acceptance of the
Company’s current and future products and services in the
marketplace, including the Company’s ability to convert successful
evaluations and tests for PURE Control and PURE Hard Surface into
customer orders and customers continuing to place product orders as
expected and to expand their use of the Company’s products; the
Company’s ability to maintain relationships with its partners and
other counterparties; the Company’s ability to generate sufficient
revenues and reduce its operating expenses in order to reach
profitability; the Company’s ability to raise the funding required
to support its continued operations and the implementation of its
business plan; the ability of the Company to develop effective new
products and receive required regulatory approvals for such
products, including the required data and regulatory approvals
required to use its SDC-based technology as a direct food contact
processing aid in raw meat processing and to expand its use in OLR
poultry processing; competitive factors, including customer
acceptance of the Company’s SDC-based products that are typically
more expensive than existing treatment chemicals; dependence upon
third-party vendors, including to manufacture its products; and
other risks detailed in the Company’s periodic report filings with
the Securities and Exchange Commission (the SEC), including its
Form 10-K for the fiscal year ended July 31, 2023, Form 10-Q for
the fiscal first quarter ended October 31, 2023, and Form 10-Q for
the fiscal second quarter ended January 31, 2024. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240801354338/en/
Mark Elliott, VP Finance PURE Bioscience, Inc. Phone:
619-596-8600 ext.: 116